Skip to main content
OpenTrials
Completed

NCT Number: NCT06854406

A Study of Varenicline in the Treatment of Visceral Sensation

The purpose of this study is to evaluate the effect of varenicline on rectal sensation, based on ascending method of limits and on graded rapid phasic distensions in participants with non-constipation IBS and chronic abdominal pain.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants will be 18-70 years of age
  • Irritable bowel syndrome with pain, but no constipation [that is IBS-D (diarrhea), IBS-M (mixed), or IBS-U (unspecified)]

Exclusion criteria

  • Diagnosis of moderate-severe depression as per HADS>8
  • Alcohol or illicit substance dependence or abuse in the past 12 months
  • Dementia, unprovoked seizure history, seizure disorder
  • Pregnancy (all women of childbearing potential will be required to have a negative pregnancy test prior to initiation, and will be on a highly effective method of contraception, as detailed in the consent form)
  • Significant change or increase in antidepressant or pain medications within the last four weeks; significant change in primary treatment interventions for pain in the past four weeks
  • Medically unstable
  • Severe hepatic or renal impairment, such as baseline AST or ALT >2.5 X upper normal limit or end-stage renal disease with estimated glomerular filtration rate or creatinine clearance <15 mL/min
  • Concomitant use of strong CYP3A4 inhibitors and strong or moderate CYP3A4 inducers

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/27/2024. Questions regarding updates should be directed to the study team contact.

Treatment and study plan

Varenicline

Drug

Initial, 0.5 mg orally once daily for 3 days, then 0.5 mg every 12 hours on days 4 through 7, and then 1 mg in morning of day 8. Medication is taken after eating and with a full glass of water.

Primary outcomes

  1. Rectal compliance

    Time frame: Comparison on day 8 of vareniciline treatment compared to baseline

    Pressure-volume relationship of rectum during balloon distension

  2. Rectal sensation thresholds during ascending method of limits

    Time frame: Comparison on day 8 of vareniciline treatment compared to baseline

    Report of rectal sensation during balloon distension 0-44mmHg

  3. Rectal sensation ratings during random order, graded phasic distensions

    Time frame: Comparison on day 8 of vareniciline treatment compared to baseline

    Report of rectal sensation during balloon distensions

Secondary outcomes

  1. Safety/adverse effects

    Time frame: 8 days

    Safety/adverse effects during administration of varenicicline

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Official study title

Varenicline in the Treatment of Visceral Sensation: A Pilot Study

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Mar 3, 2025
Registry last updated
Jan 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.